Dupilumab treatment of atopic dermatitis resulted in long-term skin improvements linked to changes in skin’s the molecular composition.

Netherlands: A recent real-world, long-term study from the BioDay Registry has highlighted a significant incidence of ...

Underlying social and economic barriers in the U.S. may play a significant role in the higher rates of atopic dermatitis.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

in Japan has granted marketing and manufacturing authorization for Dupixent ® (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...